Literature DB >> 23883213

Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: imaging features and diagnostic accuracy of contrast-enhanced CT and MRI.

Kathryn J Fowler1, Arman Sheybani, Rex A Parker, Sean Doherty, Elizabeth M Brunt, William C Chapman, Christine O Menias.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate the diagnostic accuracy of preoperative imaging for diagnosis of combined hepatocellular cholangiocarcinoma tumors and to evaluate the clinical and imaging features and demographics of patients presenting to our institution with such tumors.
MATERIALS AND METHODS: From January 2001 to January 2011, 29 patients presented with pathologically proven combined hepatocellular cholangiocarcinoma tumors to our institution. A retrospective review of the imaging studies, clinical data, and demographic information in these patients was conducted. Two radiologists with 6 and 18 years of experience reviewed the imaging studies of patients with combined hepatocellular cholangiocarcinoma tumors and matched control cases of hepatocellular carcinoma (HCC) (n = 15) and cholangiocarcinoma (n = 18). The reviewers were blinded to the pathologic diagnosis. Imaging features on contrast-enhanced MRI and CT with the suggested final diagnosis were recorded.
RESULTS: The demographics of our patient population were similar to other reported U.S. populations, with cirrhosis and hepatitis present in a minority of patients. The imaging features of combined hepatocellular cholangiocarcinoma tumors overlapped with those of HCC and cholangiocarcinoma. The correct diagnosis of combined hepatocellular cholangiocarcinoma tumors was made in a minority of cases by either radiologist, with misdiagnosis more often leading to suggestion of cholangiocarcinoma than HCC. Sensitivities and specificities for diagnosis of combined hepatocellular cholangiocarcinoma tumors ranged from 33% to 34% and 81% to 100%, respectively.
CONCLUSION: Preoperative diagnosis of combined hepatocellular cholangiocarcinoma tumors on the basis of imaging features is accurate in the minority of cases. Tumor markers and risk factors may help improve accuracy; however, in the absence of classic imaging features and supportive information for HCC or cholangiocarcinoma, biopsy should be considered for confirmation of diagnosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23883213     DOI: 10.2214/AJR.12.9488

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  60 in total

1.  Pseudolymphoma (reactive lymphoid hyperplasia) of the liver: A clinical challenge.

Authors:  Yong Kyong Kwon; Reena C Jha; Kambiz Etesami; Thomas M Fishbein; Metin Ozdemirli; Chirag S Desai
Journal:  World J Hepatol       Date:  2015-11-18

2.  Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging.

Authors:  Sun Kyung Jeon; Ijin Joo; Dong Ho Lee; Sang Min Lee; Hyo-Jin Kang; Kyoung-Bun Lee; Jeong Min Lee
Journal:  Eur Radiol       Date:  2018-06-28       Impact factor: 5.315

3.  Intrahepatic cholangiocarcinoma: expert consensus statement.

Authors:  Sharon M Weber; Dario Ribero; Eileen M O'Reilly; Norihiro Kokudo; Masaru Miyazaki; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

4.  cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation.

Authors:  Elizabeth Brunt; Shinichi Aishima; Pierre-Alain Clavien; Kathryn Fowler; Zachary Goodman; Gregory Gores; Annette Gouw; Alex Kagen; David Klimstra; Mina Komuta; Fukuo Kondo; Rebecca Miksad; Masayuki Nakano; Yasuni Nakanuma; Irene Ng; Valerie Paradis; Young Nyun Park; Alberto Quaglia; Massimo Roncalli; Tania Roskams; Michiie Sakamoto; Romil Saxena; Christine Sempoux; Claude Sirlin; Ashley Stueck; Swan Thung; W M S Tsui; Xin-Wei Wang; Aileen Wee; Hirohisa Yano; Matthew Yeh; Yoh Zen; Jessica Zucman-Rossi; Neil Theise
Journal:  Hepatology       Date:  2018-05-09       Impact factor: 17.425

5.  Lymphoepithelioma-like cholangiocarcinoma: a mimic of hepatocellular carcinoma on imaging features.

Authors:  Tsan-Chieh Liao; Chien-An Liu; Nai-Chi Chiu; Yi-Chen Yeh; Yi-You Chiou
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

6.  Histological heterogeneity in primary and metastatic classic combined hepatocellular-cholangiocarcinoma: a case series.

Authors:  Claudio De Vito; Debashis Sarker; Paul Ross; Nigel Heaton; Alberto Quaglia
Journal:  Virchows Arch       Date:  2017-07-13       Impact factor: 4.064

7.  Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.

Authors:  Yeun-Yoon Kim; Chansik An; Sungwon Kim; Myeong-Jin Kim
Journal:  Eur Radiol       Date:  2017-12-11       Impact factor: 5.315

8.  A genetic database can be utilized to identify potential biomarkers for biphenotypic hepatocellular carcinoma-cholangiocarcinoma.

Authors:  Shaffer R S Mok; Sachin Mohan; Navjot Grewal; Adam B Elfant; Thomas A Judge
Journal:  J Gastrointest Oncol       Date:  2016-08

9.  Claudins-4 and -7 might be valuable markers to distinguish hepatocellular carcinoma from cholangiocarcinoma.

Authors:  Yusuke Ono; Yutaro Hiratsuka; Masaki Murata; Akira Takasawa; Rieko Fukuda; Masanori Nojima; Satoshi Tanaka; Makoto Osanai; Koichi Hirata; Norimasa Sawada
Journal:  Virchows Arch       Date:  2016-07-21       Impact factor: 4.064

Review 10.  Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review.

Authors:  An Tang; Mustafa R Bashir; Michael T Corwin; Irene Cruite; Christoph F Dietrich; Richard K G Do; Eric C Ehman; Kathryn J Fowler; Hero K Hussain; Reena C Jha; Adib R Karam; Adrija Mamidipalli; Robert M Marks; Donald G Mitchell; Tara A Morgan; Michael A Ohliger; Amol Shah; Kim-Nhien Vu; Claude B Sirlin
Journal:  Radiology       Date:  2017-11-21       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.